GOP tax re­form bill would re­peal or­phan drug re­search cred­its

Re­pub­li­cans on Thurs­day rolled out their new tax re­form bill, which among oth­er pro­vi­sions to low­er tax­es for Amer­i­cans and busi­ness­es, pro­pos­es to re­peal a pro­vi­sion that might cause the bio­phar­ma in­dus­try some con­cern.

Un­der the House bill’s Sub­ti­tle E, sec­tion 3401 would re­peal what amounts to half of the qual­i­fied clin­i­cal re­search costs for des­ig­nat­ed or­phan drug prod­ucts.


Un­der the Or­phan Drug Act of 1983, Con­gress sought to in­cen­tivize the de­vel­op­ment of drugs to treat rare dis­eases by of­fer­ing drug­mak­ers tax cred­its, fee waivers and a sev­en-year pe­ri­od of mar­ket­ing ex­clu­siv­i­ty for an ap­proved or­phan in­di­ca­tion. To qual­i­fy for the des­ig­na­tion, a prod­uct must be in­tend­ed to treat a dis­ease that af­fects few­er than 200,000 peo­ple in the US, or more than 200,000 if the drug­mak­er can show that it is not ex­pect­ed to re­coup its costs to de­vel­op and mar­ket the drug.

In terms of the tax cred­it, a spon­sor may claim half of the qual­i­fied clin­i­cal re­search costs for a des­ig­nat­ed or­phan prod­uct. The or­phan drug cred­it is avail­able for qual­i­fy­ing costs in­curred be­tween the date the Food and Drug Ad­min­is­tra­tion (FDA) des­ig­nates a drug as an or­phan drug and the date the FDA ap­proves the drug, though the re­search cred­it can be claimed for the de­vel­op­ment costs that are qual­i­fied re­search ex­pens­es re­gard­less of FDA des­ig­na­tion or ap­proval of the drug.

Crit­ics of the law claim it has al­lowed drug­mak­ers to charge ex­or­bi­tant prices for many or­phan drugs and ar­gue that drug­mak­ers take ad­van­tage of the in­cen­tives of the law.

Be­tween 1983 and 2016, FDA ap­proved 451 or­phan drugs for 590 rare dis­ease in­di­ca­tions, though some es­ti­mate that there are about 7,000 rare dis­eases, most of which have no ap­proved treat­ments.

In 2016, FDA’s Of­fice of Or­phan Prod­ucts De­vel­op­ment (OOPD) re­ceived 568 new re­quests for des­ig­na­tion – more than dou­ble the num­ber of re­quests re­ceived in 2012. And last June, FDA pledged to elim­i­nate the or­phan drug des­ig­na­tion back­log.

Tax Bill and Com­ments

The bill’s at­tempt to re­peal the or­phan drug re­search cred­it fol­lows the re­cent re­lease of an analy­sis con­duct­ed by the US De­part­ment of the Trea­sury find­ing that to­tal tax ex­pen­di­tures from the or­phan drug re­search cred­it are bal­loon­ing.

The ex­pen­di­tures are ex­pect­ed to in­crease from about $2.3 bil­lion in 2017 to al­most $6 bil­lion in 2022 to more than $15 bil­lion in 2027.

Al­though the ex­pen­di­tures and num­ber of or­phan drug ap­provals have risen in re­cent years, in­dus­try groups have been adamant about the im­por­tance of the tax cred­it in en­cour­ag­ing or­phan drug re­search.

Ac­cord­ing to an Ernst & Young re­port from 2015, 67 or­phan drugs, or 33%, would like­ly not have been de­vel­oped over the past 30 years if there had nev­er been an or­phan drug tax cred­it.

“If the ODTC [Or­phan Drug Tax Cred­it] were re­pealed, the re­sult­ing re­duc­tion in the num­ber of ap­proved new or­phan drugs could have a sig­nif­i­cant im­pact on Amer­i­cans with rare dis­eases,” the re­port said.

James Love

In­dus­try group BIO, which col­lab­o­rat­ed on the re­port, said in a state­ment on Thurs­day, “As Con­gress de­bates and re­fines this im­por­tant leg­is­la­tion, we look for­ward to work­ing with law­mak­ers to en­sure that our na­tion’s tax code most ef­fec­tive­ly en­cour­ages in­no­va­tion, in­vest­ment and Amer­i­can en­tre­pre­neur­ship. This would in­clude main­tain­ing the Or­phan Drug Tax Cred­it.”

In a let­ter sent to Reps. Paul Ryan (R-WI) and Kevin Brady (R-TX) last week, BIO, No­var­tis, Al­ler­gan and oth­er com­pa­nies said: “We sup­port your ef­forts to re­form Amer­i­ca’s cor­po­rate tax code to make the U.S. com­pet­i­tive on the glob­al stage, in­clud­ing your dri­ve to low­er the cor­po­rate tax rate. How­ev­er, pay­ing for rate re­duc­tion by elim­i­nat­ing the ODTC would se­vere­ly ham­per our abil­i­ty to bring life-sav­ing treat­ments for rare and dev­as­tat­ing dis­eases to pa­tients. Thus, we strong­ly sup­port pre­serv­ing the ODTC in any tax re­form leg­is­la­tion.”

But the will­ing­ness of Re­pub­li­cans to take a stance against the bio­phar­ma in­dus­try al­so sig­naled to some that more re­form may be com­ing in some form.

James Love, KEI Di­rec­tor, told Fo­cus in a state­ment: “The GOP pro­pos­al to elim­i­nate the Or­phan Drug Tax Cred­it may cre­ate a new op­por­tu­ni­ty to re­form the in­cen­tives for rare dis­eases, even if the tax bill fails or the tax cred­it sur­vives. The GOP tax bill shows there is weak­er sup­port for the ex­ist­ing regime than many thought.”

First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email for more in­for­ma­tion.


Zachary Brennan

managing editor, RAPS

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.